James Auran, MD, a professor of ophthalmology at Columbia University Irving Medical Center and president of the American Society of Ophthalmic Trauma, explains what he is most looking forward to at the 2021 conference of the American Academy of Ophthalmology (AAO).
The field of ophthalmic trauma began to receive more attention around 2 or 3 years ago, explained James Auran, MD, a professor of ophthalmology at Columbia University Irving Medical Center and president of the American Society of Ophthalmic Trauma. Auran will chair a session at the American Academy of Ophthalmology's 2021 conference, taking place November 12-15, on the responsibilities of the on-call ophthalmologist.
Transcript
What are you most looking forward to at the American Academy of Ophthalmology's 2021 conference?
I'm Dr Jim Auran. I'm a professor of ophthalmology at Columbia University and I've had the honor of being president of the American Society of Ophthalmic Trauma for the past 2 years. I think what I'm looking forward to most is that we have some pretty comprehensive instruction courses going, all because of the gracious efforts of the academy to allow us to do so. We have a poster session and a symposium. Trauma has been the poor stepchild of ophthalmology for a long time. There's been a tremendous amount of interest and many people have dedicated their lives to it, but they hadn't got the traction until recently. I guess it just hit a critical point about 2 to 3 years ago and here we are.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More